Cipla announces JV with Kemwell Biopharma and Manipal Group for cell therapy development
Cipla (EU) Limited, UK, a wholly-owned subsidiary of Cipla Limited, has entered into a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & ... Read More
Cipla expands digital healthcare reach with further investment in GoApptiv
Cipla Limited, a leading pharmaceutical company, has announced its decision to further invest approximately INR 42 crore in digital tech company GoApptiv Private Limited. This ... Read More
Cipla to acquire Actor Pharma to dominate South African OTC market
In a strategic move that amplifies its commitment to the Over-The-Counter (OTC) business, Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; ... Read More
Cipla Q2 FY22 profit after tax increases 7% to Rs 665cr
Cipla Limited has reported a profit after tax (PAT) of INR 711 crores for the second quarter of the fiscal year 2022 (Q2 FY22), a ... Read More
Cipla to form respiratory biosimilars JV with Indian CDMO Kemwell Biopharma
Cipla Limited has entered into a joint venture (JV) agreement with Kemwell Biopharma, a Bengaluru-based biopharma contract development and manufacturing organization (CDMO), for developing, manufacturing, ... Read More
Roche, Cipla to bring Casirivimab/Imdevimab Covid-19 drug to India
Roche India said that India’s Central Drugs Standards Control Organisation (CDSCO) has granted an emergency use authorisation (EUA) for the Casirivimab, Imdevimab antibody cocktail for ... Read More
Cipla, Stempeutics Research to launch Stempeucel for critical limb ischemia
Cipla announced that its partner Stempeutics Research has secured regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel, a ... Read More